Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice

The 2014 Ebola outbreak in West Africa resulted in more than 11,000 deaths, highlighting the need for a vaccine. A phase I clinical trial of a human adenovirus type 5 vector-based Ebola virus (EBOV) vaccine (HAdV-5-MakGP) showed that a homologous prime-boost regimen with HAdV-5 vaccine elicited a ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Wei, Zhang, Peng, Bai, Shuang, Lv, Min, Wang, Jian, Chen, Weixin, Yu, Qingzhong, Wu, Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Vienna 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482741/
https://www.ncbi.nlm.nih.gov/pubmed/34591172
http://dx.doi.org/10.1007/s00705-021-05234-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482741/
https://www.ncbi.nlm.nih.gov/pubmed/34591172
http://dx.doi.org/10.1007/s00705-021-05234-4

Ejemplares similares